Abstract: Various methods and systems are provided for authoring and presenting 3D presentations. Generally, an augmented or virtual reality device for each author, presenter and audience member includes 3D presentation software. During authoring mode, one or more authors can use 3D and/or 2D interfaces to generate a 3D presentation that choreographs behaviors of 3D assets into scenes and beats. During presentation mode, the 3D presentation is loaded in each user device, and 3D images of the 3D assets and corresponding asset behaviors are rendered among the user devices in a coordinated manner. As such, one or more presenters can navigate the scenes and beats of the 3D presentation to deliver the 3D presentation to one or more audience members wearing augmented reality headsets.

Abstract: Apparatus and methods for generating pulse pacing in a wearable cardioverter defibrillator (“WCD”). In one aspect the WCD circuitry includes a power source such as a battery coupled to a charger that provides charge energy to an energy storage module. Control circuitry is operatively coupled to the charger and the output circuitry, and configured to cause the WCD circuitry to generate pacing pulses delivered to therapy electrodes (attached to an ambulatory patient) without a current source. The WCD circuitry includes one or more processing elements that are used to execute instructions provided by one or more software modules that are configured to support various functionality, including controlling generation of pacing pulses.

Abstract: A water filtration system is provided comprising first and second banks of water filter assemblies, wherein the system is arranged to provide filtered water from one bank of water filter assemblies while using some of the filtered water to reverse flush the other bank of water filtration assemblies. A method of filtering water by passing it through the system is also provided.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In a preferred embodiment, the invention is a mobile communication device having a digital signal processor (DSP), a speaker output node, a local audio source, and an analog front-end (AFE), wherein: (1) the DSP receives a first audio signal corresponding to sound captured by a microphone near a user of the device, (2) if the device is operating in a call mode, the DSP derives a background noise signal from the first audio signal, for subtraction from the first audio signal before transmission to the AFE, and (3) if the device is operating in a non-call mode, then the DSP (i) generates a speaker output signal which substantially corresponds to the first audio signal subtracted from a local audio signal provided by the local audio source and (ii) provides the speaker output signal to a speaker via the speaker output node.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: In a preferred embodiment, the invention is a mobile communication device having a digital signal processor (DSP), a speaker output node, a local audio source, and an analog front-end (AFE), wherein: (1) the DSP receives a first audio signal corresponding to sound captured by a microphone near a user of the device, (2) if the device is operating in a call mode, the DSP derives a background noise signal from the first audio signal, for subtraction from the first audio signal before transmission to the AFE, and (3) if the device is operating in a non-call mode, then the DSP (i) generates a speaker output signal which substantially corresponds to the first audio signal subtracted from a local audio signal provided by the local audio source and (ii) provides the speaker output signal to a speaker via the speaker output node.

Abstract: A system for, and method of, obscuring ambient noise. In one embodiment, the system includes: (1) a background sound generator, (2) a mixer coupled to the background sound generator and (3) a user interface, coupled to the mixer, that, upon a user command, causes the mixer to mix an output of the background sound generator with a transmitted signal. The background sound may be music, white noise, colored noise, out-of-phase ambient noise, simulated alternative ambient noise or any other suitable background sound. The system may be associated with a wireless handset, a wireline handset, central office equipment or any other suitable location or equipment.

Abstract: There is disclosed a keypad apparatus and a method for determining the status of a keypad apparatus. In one embodiment, the keypad apparatus includes a keypad having a plurality of keys and a keypad matrix associated with the keypad and having a switch. The keypad apparatus also includes a cover moveable between an open and a closed position. The keypad apparatus still further includes a means for engaging that cooperates with and allows the switch to provide a status indicating a position of the cover.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract: There is disclosed a keypad apparatus and a method for determining the status of a keypad apparatus. In one embodiment, the keypad apparatus includes a keypad having a plurality of keys and a keypad matrix associated with the keypad and having a switch. The keypad apparatus also includes a cover moveable between an open and a closed position. The keypad apparatus still further includes a means for engaging that cooperates with and allows the switch to provide a status indicating a position of the cover.

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.